Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities

Navid Hasani, BS^{a,b}, Faraz Farhadi, BS^a,
Michael A. Morris, MD, MS, DABR, DABNM^{a,c}, Moozhan Nikpanah, MD^a,
Arman Rahmim, PhD, DABSNM^{d,e}, Yanji Xu, PhD^f, Anne Pariser, MD^f,
Michael T. Collins, MD^g, Ronald M. Summers, MD, PhD^a,
Elizabeth Jones, MD, MPH, MBA^a, Eliot Siegel, MD, FSIIM, FACR^h,
Babak Saboury, MD, MPH, DABR, DABNM^{a,c,i,*}

KEY WORDS

• Artificial intelligence • Rare diseases • Positron emission tomography • Medical imaging

KEY POINTS

- Individually Rare, Together Common: Almost 1 in 10 individuals can suffer from one of many rare diseases (RDs).
- The RD community must be recognized and have a seat at the table of AI stakeholders.
- Physicians are expected to be able to diagnose and treat those with common and rare diseases. A similar expectation must be present for AI solutions.
- There is a significant need to recognize the challenge of data imbalance in RDs and to make concerted efforts to provide technical recommendations and guidelines.
- A nationwide RD data repository is an indispensable prerequisite for a fair AI ecosystem.
- The RD community should be protected from any misuses or abuses of AI systems that lead to discrimination.

^a Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 1C455, Bethesda, MD 20892, USA; ^b University of Queensland Faculty of Medicine, Ochsner Clinical School, New Orleans, LA 70121, USA; ^c Department of Computer Science and Electrical Engineering, University of Maryland-Baltimore Country, Baltimore, MD, USA; ^d Department of Radiology, BC Cancer Research Institute, University of British Columbia, 675 West 10th Avenue, Vancouver, British Columbia, V5Z 1L3, Canada; ^e Department of Physics, BC cancer Research Institute, University of British Columbia, Vancouver, British Columbia, Canada; ^f Office of Rare Diseases Research, National Center for Advancing Translational Sciences, National Institutes of Health (NIH), Bethesda, MD 20892, USA; ^g Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health (NIH), Bethesda, MD, USA; ^h Department of Radiology and Nuclear Medicine, University of Maryland Medical Center, 655 W. Baltimore Street, Baltimore, MD 21201, USA; ⁱ Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

* Corresponding author. Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 1C455, Bethesda, MD 20892, USA

E-mail address: babak.saboury@nih.gov

INTRODUCTION

Medicine is the art of compassionate care using scientific wisdom and the best available tools. For a physician, each patient is a unique human being, with particular past history and present manifestation. No patient is a “rare patient” or a “common patient”; each patient is a unique human being.

However, modern nosologic taxonomy makes it inevitable to categorize the constellation of clinical findings into specific diseases or syndromes (phenotyping). Here, we group multiple individuals into a specific category. This is a helpful approach because the understanding of the molecular basis of these phenotypic categories enables suitable treatment discovery and implementation. Most of the pharmaceutical treatments are, by design, appropriate for a “group of subjects with a common denominator (specific molecular pathogenesis)”.

The cognitive task for clinical medicine includes attentive observation and careful phenotyping of the patients based on their clinical, physical, biochemical, imaging, histopathological, and genetic findings altogether. The result of this process is the appropriate diagnosis. Here is the core of inherent cognitive dissonance: moving between the “unique human-being” and “grouped disease categories”; separation and connectedness at the same time. This paradoxical situation, if unaddressed, manifests itself in a plethora of “diagnostic cognitive biases.”¹

We want each patient to be considered unique and individual and at the same time as connected and included in the appropriate categories as possible. Recognition of a group of diseases as “rare diseases” is an attempt to facilitate the “inclusion” into an appropriate category when it is needed (facilitate the connectedness). Acknowledgment of individual differences and advocacy for “personalized medicine” is an attempt to enable individuation (facilitate uniqueness). These one attempts, albeit seemingly contradictory, are two sides of one reality.

Herein, we will discuss how the issue of “inclusion” could be affected by the advancement of artificial intelligence (AI) in medicine. We intend to show that the interaction between rare diseases (RDs) and AI technology is an impactful event: a potential for dreadful consequences as well as colossal progression and improvement. Which path is our path? It is difficult to predict the future but with active engagement, the future can be invented.

Suboptimal performance of AI technologies in patients with uncommon conditions can significantly hinder the clinical utility and translation of AI medical

devices into routine clinical practice.² Hence to appropriately incorporate AI into clinical practice, it is an ethical obligation to address opportunities and concerns related to the diagnosis of RD with AI-based molecular imaging. The societal, economic, and health implications of medical AI for patients with RDs can be 2-fold: (1) through the marginalization and exclusion of those with RDs (discrimination by omission) and (2) through blatant or subtle unregulated postdeployment discrimination or malicious uses of AI technologies (discrimination by commission). This paper aims to explore the medical as well as ethical and societal aspects of using RDs-aware AI in the health care system.

Prevalence and Disease Burden

The Orphan Drug Act of 1983³ classifies a condition as “rare” if it affects fewer than 200,000 people in the United States (**Fig. 1**).⁴ RDs are rare when considered individually, yet collectively they are common; they consist of more than 7000 to 10,000 identified conditions⁵ influencing more than 350 million people worldwide.⁶ The burden and urgency of the problem have also been investigated recently through the cost-of-illness studies conducted by Everylife FDN⁷ and Navarrette-Opazo and colleagues⁸ which demonstrate large medical and societal expenses as a proxy for unmet medical demands and severity of illness in patients with RDs. RDs encompass a diverse spectrum of conditions, with more than 85% being single-gene disorders and the remainder being rare malignancies, infections, exposures, and polygenic disorders.⁹ PET imaging has shown an important role in the diagnosis and management of several RDs including multiple endocrine neoplasias,¹⁰ Von Hippel-Lindau disease,¹¹ pheochromocytoma and paraganglioma (PPGL),¹² familial carcinoid syndrome,¹³ Erdheim-Chester Disease,¹⁴ and Duchenne muscular dystrophy (DMD).¹⁵

Enigma of Diagnosis

Individuals suffering from RDs often undergo numerous consultations, imaging studies, workups, and are frequently misdiagnosed before the final diagnosis is made¹⁶ – *diagnostic odyssey*. Additionally, this community suffers from sparse and dispersed medical knowledge, resulting in even fewer effective and approved treatment choices.

Physician's familiarity: Maintaining up-to-date knowledge of particular diagnostic criteria for 7000 various RDs poses a unique challenge for many physicians and specialists. The term “diagnostic odyssey” refers to the time of initial disease symptoms until the final diagnosis of RD, encompassing

RARE DISEASES

Fig. 1. Individually Rare, Together Common: Statistics related to the epidemiology of RDs and the importance of early diagnosis.

multiple physicians' consults and diagnostic tests.¹⁷ The average living person with RD endures a 6 to 7 year long diagnostic odyssey in the US.¹⁸ According to a Belgian survey, the average level of physician awareness regarding RDs is suboptimal.¹⁹ Reportedly, most physicians have the desire to diagnose and treat RDs; however, 40% of general practitioners and 24% of specialists experience a lack of sufficient time to pursue workups necessary to diagnose RD in clinical practice.²⁰ The situation is made more complicated by the fact that only a small number of clinicians with prior exposure are capable of confirming these rare disorders.

Heterogenous presentation of rare diseases: Another related concern is the heterogeneity of symptoms of each disease and sporadic presentation in the body. These factors lead to underdiagnosis or delayed diagnosis of RD. Even when the patient is suspected of having a RD, there is still a significant chance of misdiagnosis due to overlapping symptoms of many RDs.²¹ As a result of these issues, the time-to-diagnosis (TTD) of RDs is significantly prolonged.

A hypothetical solution for this problem, according to Hirsch and colleagues,²² is a symptom

checker mobile application that assesses patient symptoms to compile lists of likely diseases and subsequently gives safe next step advice. An application can provide a list of specialists, genetic testing, remote self-testing, and continuous tele-monitoring of health status, all of which could help lower the TTD of RDs and lower disease burden from this community.²²

Role of Artificial Intelligence and Medical Imaging

Recent advancements in information technology, particularly machine learning (ML), and AI have shown significant prospects of AI-based medical devices (AIMDs) in diagnosis, management, and pharmaceutical development for various diseases.^{23,24} Although these advancements have been less prominent in RDs, AIMDs have demonstrated notable results in several dimensions of common diseases (CDs) diagnosis and prognosis (eg, breast cancers, brain tumors, fractures).²⁵⁻²⁷

One reason for such lack of progress in RDs is the scarcity or heterogeneity of available data on

a particular RD. As the success of an AI algorithm is directly correlated with the quality and size of datasets,²⁸ it is imperative to address these concerns as they pertain to different types of available RD data.

Although text-mining methods may be promising in the near future, the variability in the quality of data, the heterogeneous nature of Electronic Medical Records (EMR), and the incomplete reporting of information are challenging to semantic interoperability.^{29,30} *Imaging data*, however, are often standardized, more consistent, and allow the visualization of multiple systems from multiple points of view. We see enormous potential in the imaging data (ie, MR, CT, PET, SPECT) in the training of AI algorithms as images are typically procured in large quantities and processed in a relatively standardized way, with less inter- or intra-observer variability, therefore providing a great data source for AI training.²⁴ Specifically, multivariate imaging data (Total Body PET (TB-PET)) that are often standardized can visualize multiple organ systems, which are of particular importance for RD diagnosis, and can lend itself particularly well to use in AI training.

Stigma of Diagnosis

Although RD-aware Software-as-a-Medical Device (SaMD) is the first essential step toward better integration of AI in Medicine, our responsibility does not end there and should include the prevention of potential abuses. One must be cognizant of the potential downstream effects and ethical implications of AIMD postdeployment. AIMDs enable continuous and early disease monitoring and detection; while clinically beneficial, this information can be intentionally or unintentionally misused in the context of overgeneralizations by health systems, insurance, or even stigmatization against an already vulnerable population.

Similar concerns were raised with the advent of next-generation sequencing (NGS), involving large-scale *whole-exome sequencing (WES)* and *whole-genome sequencing (WGS)*, which enabled the third-party gathering of large amounts of patient data.³¹ Sensitive medical information, when made available to a third party without proper deidentification, could potentially have negative repercussions for a person in terms of future insurance, employment, or health care opportunities. As an example, patient WGS findings have been used by heart and lung transplantation teams to decide whether to list an individual as an organ recipient.³² Yet, despite the recommendation of the Americans with Disabilities Act (ADA)³³ and Genetic

Information Nondiscrimination Act (GINA)³⁴ reportedly, many transplant programs across the US continue to be biased and discriminate against those with intellectual and genetic diseases.³⁵

Therefore, the issue of data protection and ownership becomes more crucial than ever. It is not far-fetched to assume that many families and patients would have a similar response to AI-based diagnosis or management if they think the results and findings would be used to stigmatize or ostracize them. This foreseeable consequence and potential stigmatization of AI should be disclosed by the team before the testing is conducted. In the case of genetic testing, many families asserted that had they known the results of WGS to potentially jeopardize the transplantation option, they would have never given consent to testing. This argument further supports the notion that the information regarding third-party use of patient data must be a part of the informed consent form. Publicly available informed consent forms can provide substantial benefit and legal protection in court if information is used for discrimination.

RARE DISEASES & ARTIFICIAL INTELLIGENCE OPPORTUNITIES AND CHALLENGES

In this section, we initially explore the bioethics of RDs in AI, and then discuss the reasons why the medical AI industry and the RD community should actively collaborate in this new era of AI in medicine. We begin by outlining the reasons why the AI community should create medical devices that are RD-aware which can diagnose RD with the same accuracy as CDs.

Ethical Considerations Related to Artificial Intelligence-Based Diagnosis and Management of Rare Diseases

- a. *Exclusion*: The scarcity of diverse representation in precision medicine and other biomedical research has been a well-known problem.³⁶ Ethical AI is diverse in its training data and performance outcomes.³⁷ Lack of inclusion of RDs in AIMDs does not align with bioethical values of *beneficence* and *justice*. For instance, rare genetic variants and uncommon conditions may be overlooked or their association with common, complex diseases can be misinterpreted.³⁸ The exclusion of patients with RDs at the training stage of the AI system subsequently leads to worse performance due to sampling bias and the absence of generalizability. Additionally, this inclination can create bias in future medical studies conducted based on AI-produced data. To maximize clinical

benefits and minimize harm, the SaMD must perform with safety (to prevent injuries and hazards), efficiency (able to effectively solve the problem at a reasonable cost), and equity (that the advantages of the application are shared fairly by all).³⁹ Thus, the deployment of AI that excludes a subgroup of individuals would diverge from any progress toward the goal of maximizing clinical benefits and addressing health inequities in historically neglected populations.

- b. *Stigmatization*: Personal health information (PHI) handled and enhanced by AIMDs must not be used against the patient for insurance, employment, delaying, or denying of medical care.⁴⁰ For example, there are differences across transplant programs when it comes to the availability of standards and listing policies for genetic diseases and intellectual disabilities.³⁵ Confidentiality transgressions with unethical usage of PHI may occur endangering the social fabric of this already disadvantaged community of patients with RDs.
- c. *Consent for revealing incidental findings by rare diseases-aware artificial intelligence*: AI can open the door for vast amounts of patient data and sensitive information to play a role in clinical decision making.⁴¹ The chance of incidental findings is inherent in medical imaging studies. Using AI-based detection algorithms can further enhance rates of incidental findings in these studies. The discovery of early signs of RDs could be among incidental findings detected in imaging studies with the assistance of RD-aware detection algorithms. For example, an automatic AI-based whole-body PET/CT ordered for the staging of a tumor can detect a new disease that was not expected at the time of testing. Are we obligated to reveal the new information to the patient? If not, how much information should the clinician reveal to the patient? Revealing the data we did not intend to find to patients has ethical and psychological implications that need to be addressed. Clear communication regarding the use of AI findings is necessary for all patients including those with RDs. This is because the health provider and patients' knowledge of AI capabilities and expectations of use of AI findings may often be different. Regardless of the fact that there is significant discussion regarding what findings should be returned, patients will have vastly diverse experiences based on which physicians and health care professionals they received care from. The same issues were present for NGS.⁴² We must learn from the

implementation of NGS in clinical practice for the successful translation of AI into precision medicine and RD diagnosis and management.

Why Should the Artificial Intelligence Community Recognize Rare Diseases as One of the Stakeholders?

To achieve the full potential of these technologies and create a sustainable AI ecosystem, AI medical devices should be integrated into an ethical platform that patients and physicians can trust [Navid Hasani and colleagues article, *Trustworthy Artificial Intelligence in Medical Imaging*, in this issue].^{43,44} There are 5 reasons why the AI industry in health care needs to consider the inclusion of RDs:

- (1) The Food and Drug Administration (FDA) and the scientific community are aware that the performance of an AI medical device depends on the training data. It is not far-fetched that the effectiveness of an AI trained and evaluated on common conditions will be incapable of use in RDs. Thus, by neglecting RDs at the AI training and development stage, the developer is unable to claim any application of the algorithm for the diagnosis or management of those with RDs.
- (2) The RD community is vulnerable and has been historically neglected by researchers, drug developers, medical specialists, and policy-makers.⁴⁵ There are substantial disease and financial burdens placed on surviving patients diagnosed with an uncommon disease and their families.⁴⁶ Therefore, in the era of AI in medicine, it is imperative to use advancements of AI-based medical imaging to appropriately diagnose and manage patients with RDs, minimizing the magnitude of potential harm to this underserved population.⁴⁷
- (3) If RDs are neglected and AI is deployed into health care, the potential absence of accurate and consistent RD-related diagnosis may worsen an already devastating situation. This would have significant negative implications for both the RD and the AI community which hinders the society's and medical community's trust in AI. When patients refer to their physician for certain symptoms, they expect an accurate diagnosis. If the physician works with an AI-based medical imaging device system that can assist in the diagnosis of diseases, that device must be accurate in detecting RDs as similarly expected for CDs. Otherwise, when AI encounters an uncommon disorder phenotype it may depict aberrant behavior, categorize the phenotype into a

CD group, or label it as unknown. Diversity in data includes the diversity of ethnic groups, genders, ages, and diseases. In terms of disease diversity in training data, there must be an assorted range of rare and common illnesses that the AIMDs can detect.⁴⁸ Inability to do so due to an underrepresentation of uncommon conditions can conceivably induce biases in the performance and evaluation of disease burden.⁴⁹ AI developers must be aware of such biases to avoid potential AI-induced discrimination further widening the health disparity gap.⁵⁰

- (4) As sustainable growth of AI in society needs the definition of trustworthiness, it is ethical and obligatory to consider RDs. The advent of AI tools and their associated abilities have created a new *ethical* and *social obligation* for intelligent interventions that, if leveraged appropriately, can significantly improve RD-related diagnosis, treatment, and patient support systems. Suboptimal performance of an AI diagnostic tool that disproportionately impacts the RD community would substantially limit translation to clinical practice as well as trustworthiness of AIMDs in health care.²²
- (5) The inclusion of RDs and data diversity Improves the robustness of AI systems and their utility in a variety of clinical settings. Enhanced performance of such systems contributes to a more diverse market, hence more profitable for AI developers. Therefore, the financial and social advantages of accurate and successful AI medical devices would be beneficial for the AI community and developers. Furthermore, studying and gathering data on RDs can provide insights into the intricacies of biological mechanisms underlying many CDs which can be leveraged by the developers to further improve the performance and robustness of future AIMDs.

Why Should the Rare Disease Community Want to Be an Active Stakeholder in the New Era of Artificial Intelligence in Medicine?

Now, let us examine this from the perspective of the RD community and patient advocacy groups. Patients with RDs confront a number of significant challenges: late diagnosis and misdiagnosis, limited disease-modifying therapies, proper response to therapies, valid monitoring tools as well as little private-sector R&D and public health prioritization due to a low number of diagnosed patients in each disease category.^{51–53} The power of AI can be used to address these obstacles. As such, the implications of AI in health care are

critical for RD diagnosis and management. This period can be the best or the worst of times for RDs diagnosis and management.

There are great opportunities for the inclusion of RD data into AI-based diagnostic tools, especially considering the growing complexity of medical data (*Big Data*)⁵⁴ and advancements in deep learning. AI tools can analyze and learn from large and complex datasets for quantitative assessment purposes⁵⁵ such as using PET for objective detection and characterization of neuroendocrine tumors.⁵⁶ AI-based decision support systems may be developed to assist clinicians in their differential diagnosis of RD.²¹ Other algorithms can assist in therapeutic research and development (i.e. *human-on-a-chip* or *clinical-trial-on-a-chip*).^{57,58} Recent AI research in meta-learning has demonstrated unprecedented success in training AI with limited data (to mimic the scenario for RD) using discriminative ensemble learning, fast few-shot transfer learning, and generalized zero shot learning (ZSL) for chest X-ray diagnosis.^{59–61}

Table 1 provides a short list of examples of how ML and AI algorithms are currently being used to further advance RD screening, treatment, and research.

At the same time, most efforts in the era of AI in medicine are focused on advancing CD diagnosis and management, neglecting the inclusion of RDs. This is an essential detail because, at a time whereby AIMDs are progressively developed and incorporated into clinical practice, we must highlight the maleficence of using AIMDs not capable of detecting RDs as accurately as CDs. As such, the deployment of AI tools into clinical practice could bear detrimental impacts on patients with undiagnosed RDs. Considering the *automation bias* associated with AI in health care, reliance on AI systems incompatible with RDs may promote misdiagnosis or *prolong the TTD* for undiagnosed patients with RDs.⁷⁰ A prolonged TTD not only exacerbates suffering but also can lead to further financial and health debilitation of patients and families.¹⁶

HOW TO ENABLE THE DEVELOPMENT AND IMPLEMENTATION OF RARE DISEASES-AWARE ARTIFICIAL INTELLIGENCE SOLUTIONS

Outreach and Collaboration with all Stakeholders

In a sustainable AI ecosystem, active collaboration exists between all stakeholders throughout the lifecycle of AIMDs. The recognition and inclusion of RD patient advocacy groups (PAGs) in the circle of stakeholders are important and must be

Table 1
Tangible examples of AI improving RD diagnosis and management

Title	Description
Symptoms checker website	AI-based applications allow patients or physicians to input presenting symptoms to determine the probabilistic differential diagnosis based on various RD databases. ⁶²
RD diagnosis support using facial features	Gurovich and colleagues ⁶³ proposed a novel facial recognition algorithm called DeepGestalt, powered by FDNA inc., that classifies distinct facial features from photos of individuals with rare neurodevelopmental and congenital disorders. The phenotypic analysis algorithm is trained on 100,000 images and can distinguish between 200 different rare syndromes achieving 91% accuracy in identifying the correct diagnosis in the top 10 suggestions. ⁶³
AI for RD drug repurposing	Lee and colleagues ¹²¹ used the URSAMD (unveiling RNA sample annotation for human diseases) machine learning framework to apply genetic and molecular information from hundreds of complicated conditions to medication repurposing. Similarly, Ekins and colleagues created an end-to-end ML algorithm that leverages ⁶⁴ large quantities of screening data to predict bioactivities for therapeutic targets and molecular properties with increased levels of accuracy.
AI-based genetic devices	The ML algorithm “Xrare” proposed by Li and colleagues ⁶⁵ jointly uses phenotypic and genetic evidence for the identification of causative gene variants in RDs and the prioritization of these diagnoses.
AI-based Human-on-a-chip and Clinical-Trial on-a-Chip drug development	Almost 95% of RDs do not have an approved treatment option ⁶⁶ . Recent AI systems have shown great promise in promoting drug development or repurposing of available therapeutics. For example, the human-on-a-chip (Hoac) or organ-on-a-chip ^{58,67} is a novel CNN-based model that mimics human organ functionality in interconnected in-vitro bioengineered micro-physiological systems. This medical imaging technology can recapitulate clinical trials on a chip (CToCs) ⁶⁸ lowering the costs and recruitment barriers related to conducting RD clinical trials (scarce number of RD patients) ⁵⁷ . This technology promotes research and development of novel PET radioactive tracers for tumor detection and treatment by introducing human phenotypic models early in the drug discovery process.
AI and PET Enables Orphan Drug Development	AI-based PET kinetic modelings have the potential to yield valuable data regarding the pharmacokinetics of investigational pharmaceuticals with a small number of participants.

(continued on next page)

Table 1
(continued)

Title	Description
Radiophenomics: AI-based medical imaging for recognition of rare disease manifestation	TB-PET powered with AI capabilities has enormous potential to identify imaging patterns suggestive of rare diseases phenotypes. Therefore, using image-based phenotyping (radiophenomics) the AI can suggest a possibility of a rare disease pattern to the physician.
AI-based medical imaging <u>management</u> of rare diseases	Pretest probability is the likelihood of having a condition before the results of a diagnostic test are known ⁶⁹ . AI algorithms can be trained to understand the pre-test probability and incorporate it into screening and management in individuals with rare diseases. The accuracy of the probability scale generated by AI and the ideal threshold used on the image may vary depending on the pre-test probability.

enforced by appropriate regulatory committees. Stakeholders involved and affected (directly or indirectly) throughout the lifecycle of AI include patients, physicians, and all the relevant providers, health care systems, payors, regulatory agencies, professional societies, and patient groups. Inclusive, transparent, and active engagement of these stakeholders throughout the development, design, and postdeployment surveillance of AI systems is needed. Patient advocacy groups specific to each RD are trusted by patients and physicians and can provide substantial assistance in building trust in using AI to diagnose RDs. By active engagement, RD patient leaders and PAGs can communicate concerns related to denying or delaying health care services through discussions with stakeholders and regulatory agencies.

There must be clear and continuous outreach efforts to educate patients regarding AI advancements in RD diagnosis and treatments.⁷¹ Grass-root organizations should educate the RD community and patients on the challenges and opportunities of AI-based RD diagnostic tools while building trust and helping to identify inappropriate adoption of AI in health care. Patient advocacy groups can be used as a liaison between the needs of patients with RDs, physicians, and the AI development industry.

To further advance the utility of AI tools in health care, continuous medical education is necessary. Such efforts directed toward medical professionals can facilitate the timely diagnosis and treatment of patients with RDs in outpatient and

inpatient settings.⁷² Clinicians should be able to maintain a baseline knowledge of RDs and keep up to date with new treatments and diagnostic tools. PAGs and organizations can convey the current state of art AI-based RD diagnosis to physicians and request that knowledge is transferred from physicians to the patients.

The National Organization of Rare Diseases (NORD), Genetic Alliance (GA), the Chan Zuckerberg Initiative⁷³ are instrumental in increasing the capacity of RD patient groups, issuing policies, and incentivizing industry for more efforts toward diagnosis and treatment of RDs.^{72,74} NORD now consists of more than 2000 and the GA more than 600 patient advocacy organizations.^{75,76} In addition to advocating for RD, these organizations can also collaborate with developers and physicians to raise awareness for AI-based diagnosis and strategies to apply AI powers to use the limited amount of available data to better treat RDs.

Rare Diseases Data Meta-Repositories

The ability of AI technologies to integrate and analyze data from different structured and unstructured sources (eg, radiomics, patient registries, anecdotal evidence, genetic variation, and molecular profiling)^{77,78} can be used to overcome RD data challenges (eg, low diagnostic rates, limited number of patients in each RD category, geographic dispersion, and heterogenous clinical presentation). Nevertheless, there is a lack of central RD data repositories for AI training.²³ Although

there are specialized repositories in existence, such as The Cancer Imaging Archive (TCIA),⁷⁹ it is vital to further expand the availability of similar datasets for RD and link different types of data together for each patient.

Sharing of anonymized health data sets enables a deeper and broader understanding of the nature of RD and affected patient populations.⁸⁰ The move toward “Big Data” provides substantial evidence for advancing model training and tuning, shortening the TTD, clinical outcomes, as well as the development of treatments for RDs.⁸¹ Patients are often supportive of safe and transparent sharing of their anonymized electronic health records (EHR) for research.⁸² Consenting to PHI sharing, as Figueiredo states, may also be a method of repaying society’s investment in science through public-funded research or charity.⁸³ To this end, it is a *social responsibility* of public institutions, private centers, schools, hospitals, etc. to share their high-quality, exquisitely curated, privacy-preserved diverse health and consumer data on patients with RDs for curating a central RD and CD data repository for AI training and testing. Professional societies (e.g. Society of Nuclear Medicine and Molecular Imaging (SNMMI), Society of Imaging Informatics in Medicine (SIIM), Radiological Society of North America (RSNA), and American Medical Informatics Association (AMIA), among others) can help address institutional *barriers to data sharing* and act as a liaison between stakeholders and associated organizations.

The National Institutes of Health (NIH) are also committed to providing long and short-term support to the RD community and to promoting AI research in areas whereby there may otherwise be insufficient attention or action.⁸⁴ To achieve this goal, *NORD* and the Rare Disease Clinical Research Network (RDCRN)⁸⁵ at the National Center for Advancing Translational Sciences (NCATS) have curated RD registries that are available for patients, researchers, and clinicians.⁸⁶ Such registries not only facilitate communication between health care professionals, patients, and the multi-disciplinary team but also highlight critical aspects of data quality, governance, and access.⁷⁷

Rare Diseases Awareness at Artificial Intelligence Conceptualization/Development Stage

It is of utmost importance for RDs to be considered in all stages of model and decision support system development. Specifically, RD awareness at the design stage relates to the inclusion of RDs alongside CDs in datasets used for model

training, validation, and testing of performance. The model should be able to categorize each disease pattern into a certain identified rare or CD pattern. For example, the AI-based imaging device should be able to perform a classification task related to RD and CD identification with reasonable accuracy and precision. For an AI-based imaging device, RD categories must be included in image recognition, annotation of radiomics, disease ranking, diagnosis, and prediction. To accomplish this, the diversity of RD and CD patterns must be included in the derivation and validation of AI models. This conceptualization minimizes chances that a rare event or incidence triggers either an *aberrant error*, is misplaced into a CD category based on resemblance, or is identified as an unknown pattern.

Class imbalance

Inductive approaches are employed in computational phenotyping algorithms to find correlations or patterns within datasets. The diagnostic accuracy and informative value of the resulting phenotyping tools are determined by the amount, variety, and accuracy of data used in model training and testing.⁸⁷ As a result, creating a representative database for algorithm training is critical to the effectiveness of computational phenotyping in RDs.⁸⁸ However, inherent to RDs, available sample sizes for the training of algorithms are often limited. This leads to class imbalance issues. Through multi-institutional collaborations (direct sharing of data and/or use of federated learning), physicians and scientists should make efforts to address this limitation. In any case, even with much needed concerted efforts, class imbalance problems are likely to persist.

To tackle this, first, we note that poor performances in class imbalance problems can be hidden if limited metrics are used for assessment; for example, for an AI algorithm that performs poorly at detecting a rare minority class, overall area-under-the-receiver-operator-characteristic-curve (AUC ROC), accuracy or specificity used as metrics may still show excellent performances (“the accuracy paradox”), due to the dominance of the majority class (e.g. healthy patients or CD). As such, a range of evaluation metrics especially those de-emphasizing true negatives (i.e. correctly classified majority class) should be reported such as recall, precision, F1 score, false-discovery rate, and the area-under-the-precision-recall-curve (AUC PR)⁸⁹ to better reveal poor performances of AI algorithms in class imbalanced datasets.

To tackle poor performances in class-imbalanced problems, computational methods

including majority class undersampling and/or minority class oversampling/data augmentation can be invoked (e.g. SMOTE,⁹⁰ ADASYN⁹¹). In particular, data augmentation can be performed on the training data to increase the size of datasets and limit overfitting. Conventional techniques of image transformations can be used such as rotating, cropping, and zooming.⁹² Additionally, AI itself might be capable of providing solutions to this matter; for example, using Generative Adversarial Networks (GANs) as used in many disciplines to generate new, synthetic instances of data that can pass for real data⁹³ and used for data augmentation purposes.⁹⁴ Use of AI-based Style Transfer⁹⁵ for data augmentation can also be further explored.

Instead of augmenting/manipulating the datasets directly, it is also possible to use other techniques that enhance the overall model architecture, making it more suited for a class-imbalanced problem. Some of these include using weighted loss functions such as the focal loss⁹⁶ that gives different weights for calculating the loss values related to the majority and the minority classes or using penalized models such as cost-sensitive support vector machine (SVM)⁹⁷ with inbuilt hyperparameters that can be weighted as per the importance of each class (with the minority class getting more weight). Certain other techniques such as anomaly detection⁹⁸ attempt to solve this issue by redefining the class-imbalance problem (i.e. with a majority and a minority class) into a problem of outlier/novelty detection (with the minority class being the outlier/novelty) in a normal (majority class) dataset.

To this end, while training an AI algorithm, the prevalence and/or importance of RD can be further enhanced (as discussed above), enabling the derivation of AI models that are effective in detecting common conditions as well as uncommon diseases. This approach is similar to the expectation that exists in medical education, including board certification examinations, to train physicians that are capable of diagnosing and treating patients with CDs as well as RDs. Therefore, it is critical to recognize this challenge and to make active efforts to provide technical best practice recommendations and guidelines.

Oversight and Regulation

Appropriate development and deployment of AI-based medical tools necessitate continuous ethics, safety, and performance assessment by objective oversight and evaluation frameworks

that are inclusive of RDs. At this exciting transitional stage, whereby AI is increasingly used in health care across the world, there are numerous opportunities compounded with AI governance difficulties.⁹⁹ The federal and local policies are often not able to keep up with the exponential growth of AI technology in health care. For this reason, a regulatory agency or public organization can ensure the proper implementation of AI-aware policies for RD diagnosis and treatment. The creation of legislation may potentially follow an industrial and political complex path¹⁰⁰ and must address the collective needs of patients with RDs. In regard to the US, the regulation of drugs, biologics, and devices are predominantly overseen by the FDA.⁴⁴

One aspect of regulation for RD-aware AI entails inclusivity monitoring, which can be conducted either by the FDA or an independent professional credentialing organization similar to the certification and recertification of medical professionals. The regulatory body should ensure the generalizability of the AI to all patients suffering from a particular condition regardless of extraneous personal characteristics. Individuals who are underrepresented or suffer from RDs should not be excluded from the creation, assessment, and deployment stages of AI systems. Appropriate validation testing on standardized sets that include a diverse patient population, including rare or unusual presentation of disease, is critical to assess for the presence of bias in results.^{37,48} More specifically, the oversight must include the assessment of performance that is, equitable, diverse, and includes relevant CDs and RDs. To achieve this goal, oversight can enforce and monitor the safety, security, ethics of SaMDs at every stage of conceptualization, development, and deployment.^{88,99}

Another highly important regulatory aspect pertains to information security and the nondiscriminatory use of AI for RD diagnosis and management. If AI-based medical imaging systems improve the diagnostic capabilities for RDs, the knowledge of this RD cannot be used by third parties to pose potential health, financial, or societal harm (stigmatization) toward the individual. Thus, the implementation of AI systems in health care will require a recalibration of confidentiality and other core tenets of professional ethics. As discussed previously, gathering more complex medical information on patients with RDs require legal protection against unintended harm (i.e. available informed consent forms). Due to the novelty of AI in medicine, there have not been many legal cases against AI, however,

predictably, potential unintended discrimination and stigmatization can happen as the result of widespread AI use in medicine. Patients with RDs are even more prone to discrimination and have been previously neglected care and treatment due to their illnesses or survival rates. Medical programs and health institutions should rethink their strategy, ensuring individualized evaluations and preventing the exclusion of patients based on their RD group membership.³⁵ Additionally, AI-based diagnosis of a RD and associated data should not be used to discriminate against this group or deny or delay care. We need to create legal protections for vulnerable populations including those with diagnosed RDs. Acknowledgment and adoption of policies similar to the Genetic Information Nondiscrimination Act (GINA)¹⁰¹ that prohibits discrimination by health insurance and employers for information for medical AI may be imperative if we are to prevent harm before the deployment of AI for the management and diagnosis of RDs.

EMERGING APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN MOLECULAR IMAGING OF RARE DISEASES

Synergism of Artificial Intelligence and Positron Emission Tomography to Accelerate Orphan Drug Development

Less is different

Orphan drug development is not merely drug development on a smaller scale. The challenges

are not just the limited market.¹⁰² Here, *less is different*. Considering the limited number of affected individuals eligible for clinical trials, translation of preclinical targets to clinical phase studies requires extra care (*precise translation*).¹⁰³ Drug development, in general, benefits from AI for more successful target selection¹⁰⁴ as less than 9% of investigational drugs entering phase 1 clinical trials reach the FDA approval.¹⁰⁵ For CDs, this is an improvement but for RDs, it is essential: population-based data for physiologically based pharmacokinetic modeling might be insufficient and the limited number of eligible candidates makes the pharmacokinetic estimations more prone to error due to smaller sample size and sparse data. AI-based PET kinetic modelings have the potential to produce valuable data regarding the pharmacokinetics of the investigational drugs with a limited number of subjects by the implementation of TB-PET dynamic imaging (Figs. 2 and 3).¹⁰⁶ The depth of such information in addition to AI-augmented pharmacochemistry provides a platform for nuanced structural fine-tuning of the selected target.¹⁰⁷ In summary, advanced computational techniques in systems biology and multi-scale modeling in addition to the novel technology of dynamic TB-PET imaging and AI-empowered complex systems modeling can aid in the creation of virtual replicates of patients, also known as digital twins.^{78,108}

Fig. 2. Total-body parametric images estimated from a 60-min dynamic ^{18}F -FDG scan of a patient with metastatic cancer on the uEXPLORER: (A) SUV, (B) FDG net influx rate K_i , (C) fractional blood volume v_b , and (D) FDG delivery rate K_1 . (From Wang Y, Li E, Cherry SR, Wang G. Total-Body PET Kinetic Modeling and Potential Opportunities Using Deep Learning. PET Clinics. 2021;16(4):613 to 625.: with permission.)

Fig. 3. High-temporal resolution Patlak plot and parametric imaging.³⁰ (A) Patlak plot of 1-h dynamic FDG data; (B) zoom-in of the first 2-min data; (C) parametric images of the slope at 3 different phases—standard K_i (30–60 minutes), first-pass K_i (20–30 s), and early-time K_i (1–2 minutes). Shown are the MIP images. The unit of K_i is mL/min/mL. (From Wang Y, Li E, Cherry SR, Wang G. Total-Body PET Kinetic Modeling and Potential Opportunities Using Deep Learning. PET Clinics. 2021;16(4):613 to 625.: with permission.)

Diagnosis of Rare Diseases with Artificial Intelligence and Molecular Imaging- Can We Shorten the Diagnostic Odyssey?

The multi-regional nature of routine PET images (from the base of skull and neck, through chest, abdomen, and pelvis to the upper aspect of thighs) provides comprehensive coverage to combine various imaging findings in many organs and assemble a multi-regional multi-organ pathology profile. Such information is invaluable for image-based phenotyping (radiophenomics). A simple suggestion by the AI software can remind the nuclear medicine physician of a possibility of a RD pattern and this may trigger a further investigation if deemed appropriate based on other clinical findings.

Artificial Intelligence-Based Positron Emission Tomography Solutions for Management of Patients with Rare Diseases

It is crucial to develop RD-specific AI algorithms that understand the *pre-test probability* of screening and diagnosis in patients with RDs. For instance, as a medical imaging physician is reviewing an imaging study of a patient with MEN2A syndrome, abnormal adrenal gland findings could be more for an adrenal malignancy. AI

algorithms should be developed to use radiomics information to incorporate such clinical information pertinent to the management of patients with RDs.¹⁰⁹ Both the accuracy of the probability scale (i.e. 70% chance of MEN2A) and the optimal threshold that is applied to the image may vary based on the pretest probability.

PET is an important imaging modality in management of patients with RDs,^{110–112} such as multiple endocrine neoplasia syndromes (MEN1, MEN2A, MEN2B),¹¹³ tumoral calcinosis,¹¹⁴ Von-Hippel Lindau (VHL),¹¹⁵ familial carcinoid syndrome,¹¹⁶ metastatic pheochromocytoma, and paraganglioma,¹¹⁷ hemangioendothelioma, and other hereditary cancer syndromes.¹¹⁸ Appropriately employing the capabilities of AI in conjunction with PET could improve monitoring and management of RDs. AI-based PET models have already shown to be capable of performing segmentation, detection, and classification tasks more objectively and efficiently than expert clinicians.^{119,120,121}

SUMMARY

If applied properly, AI-based Positron Emission Tomography (PET) has enormous potential to revolutionize the detection and management of RDs, particularly considering the richness of data in

emerging TB-PET.^{122,123} However, the RDs community and stakeholders must be recognized and present at the table of AI stakeholders. A national archive of RD data is a necessary precondition for a just AI environment. AI medical systems should provide a clear notice stating that any differential diagnostic support system may miss some RDs, if not appropriately trained and validated. There should be technical guidelines on data augmentation for AI training, including a greater proportion of RD data in training sets than is currently the case. The RD community should be safeguarded against any exploitation or abuse of AI systems that result in discrimination toward those living with these conditions. This could be accomplished in a variety of ways, including teaching medical/scientific communities' ethical leaders about the critical nature of RD inclusion, as well as through regulatory mandates.

CLINICS CARE POINTS

- Medicine is the art of compassionate care using scientific wisdom and the best available tools. AI medical devices (AIMDs) are among those tools. It is the responsibility of physicians and healthcare system to understand the beneficial uses and dangerous misuses of this new technology, particularly in relation to the rare disease community.
- If the performance of AIMDs is not evaluated in rare diseases carefully, there might be an ethical obligation to disclose the potential harms (for example, the device could have a clear disclaimer stating that some RDs may be missed in the differential diagnosis support system).
- The rare disease community should be recognized as a stakeholder in the lifecycle of AIMDs and they should be involved in all phases of development, deployment, and oversight.
- AI solutions for RD patients could be actualized through sustainable cooperation among all stakeholders (from creation of data meta-repositories, to social awareness at all phases of development and implementation).

ACKNOWLEDGMENTS AND DISCLOSURES

This research was supported in part by the Intramural Research Program of the NIH, Clinical Center. The opinions expressed in this publication are

the author's own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government.

The authors acknowledge valuable feedback by Shadab Ahamed on the class imbalance problem. The authors acknowledge and thank Dr. David Magnus for his contributions.

REFERENCES

1. Kwok ESH, Calder LA, Barlow-Krelina E, et al. Implementation of a structured hospital-wide morbidity and mortality rounds model. *BMJ Qual Saf* 2017;26(6):439–48.
2. Sharma N, Aggarwal LM. Automated medical image segmentation techniques. *J Med Phys* 2010; 35(1):3–14.
3. Act C. Orphan drug act of 1983. Public L 1983;97: 414. Available at: <https://www.fda.gov/media/99546/download>.
4. Office of the Commissioner. Rare diseases at FDA. Available at: <https://www.fda.gov/patients/rare-diseases-fda>. Accessed July 6, 2021.
5. Ekins S. Industrializing rare disease therapy discovery and development. *Nat Biotechnol* 2017; 35(2):117–8.
6. RARE facts. Available at: <https://globalgenes.org/rare-facts/>. Accessed July 6, 2021.
7. Burden of Rare Disease Study - EveryLife Foundation for Rare Diseases. Available at: <https://everylifefoundation.org/burden-study/>. Accessed September 18, 2021.
8. Navarrete-Opazo AA, Singh M, Tisdale A, et al. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. *Genet Med* 2021. <https://doi.org/10.1038/s41436-021-01241-7>.
9. FAQs about rare diseases. Available at: <https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-diseases>. Accessed September 18, 2021.
10. Multiple endocrine neoplasia type 1 - NORD (national organization for rare disorders). 2015. Available at: <https://rarediseases.org/rare-diseases/multiple-endocrine-neoplasia-type-1/>. Accessed July 21, 2021.
11. Von Hippel-Lindau Disease - NORD (National Organization for Rare Disorders). 2015. Available at: <https://rarediseases.org/rare-diseases/von-hippel-lindau-disease/>. Accessed July 21, 2021.
12. Pheochromocytoma - NORD (National Organization for Rare Disorders). 2015. Available at: <https://rarediseases.org/rare-diseases/pheochromocytoma/>. Accessed July 21, 2021.
13. Carcinoid syndrome - NORD (national organization for rare disorders). 2015. Available at: <https://rarediseases.org/rare-diseases/carcinoid-syndrome/>. Accessed July 21, 2021.

- rarediseases.org/rare-diseases/carcinoid-syndrome/. Accessed July 21, 2021.
14. Erdheim Chester Disease - NORD (National Organization for Rare Disorders). 2015. Available at: <https://rarediseases.org/rare-diseases/erdheim-chester-disease/>. Accessed July 22, 2021.
 15. Duchenne muscular dystrophy - NORD (national organization for rare disorders). 2015. Available at: <https://rarediseases.org/rare-diseases/duchenne-muscular-dystrophy/>. Accessed July 21, 2021.
 16. Black N, Martineau F, Manacorda T. Diagnostic odyssey for rare diseases: exploration of potential indicators. Available at: <https://piru.ac.uk/assets/files/Rare%20diseases%20Final%20report.pdf>. Accessed July 7, 2021.
 17. Contributor G. The rare disease diagnostic odyssey: a medical student's perspective. Available at: <https://www.findacure.org.uk/2018/07/06/the-rare-disease-diagnostic-odyssey-a-medical-students-perspective/>. Accessed July 6, 2021.
 18. The Lancet Diabetes Endocrinology. Spotlight on rare diseases. *Lancet Diabetes Endocrinol* 2019; 7(2):75.
 19. Vandeborne L, van Overbeeke E, Dooms M, et al. Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. *Orphanet J Rare Dis* 2019;14(1):99.
 20. Hempel H. Accurate diagnosis of rare diseases remains difficult despite strong physician interest. 2014. Available at: <https://globalgenes.org/2014/03/06/accurate-diagnosis-of-rare-diseases-remains-difficult-despite-strong-physician-interest/>. Accessed July 22, 2021.
 21. Alves R, Piñol M, Vilaplana J, et al. Computer-assisted initial diagnosis of rare diseases. *PeerJ* 2016;4:e2211. <https://doi.org/10.7717/peerj.2211>.
 22. Hirsch MC, Ronicke S, Krusche M, et al. Rare diseases 2030: how augmented AI will support diagnosis and treatment of rare diseases in the future. *Ann Rheum Dis* 2020;79(6):740–3.
 23. Brasil S, Pascoal C, Francisco R, et al. Artificial intelligence (AI) in rare diseases: is the future brighter? *Genes* 2019;10(12). <https://doi.org/10.3390/genes10120978>.
 24. Schaefer J, Lehne M, Schepers J, et al. The use of machine learning in rare diseases: a scoping review. *Orphanet J Rare Dis* 2020;15(1):145.
 25. Becker AS, Marcon M, Ghafoor S, et al. Deep learning in mammography: diagnostic accuracy of a multipurpose image analysis software in the detection of breast cancer. *Invest Radiol* 2017;52(7):434–40.
 26. Comelli A, Stefano A, Russo G, et al. A smart and operator independent system to delineate tumours in positron emission tomography scans. *Comput Biol Med* 2018;102:1–15.
 27. Kijowski R, Liu F, Caliva F, et al. Deep learning for lesion detection, progression, and prediction of musculoskeletal disease. *J Magn Reson Imaging* 2020;52(6):1607–19.
 28. Cortes C, Jackel LD. Limits on learning machine accuracy imposed by data quality. Available at: <https://www.aaai.org/Papers/KDD/1995/KDD95-007.pdf>. Accessed July 19, 2021.
 29. Shinozaki A. Electronic medical records and machine learning in approaches to drug development. In: Cassidy JW, Taylor B, editors. *Artificial intelligence in Oncology drug discovery and development*. IntechOpen; 2020. <https://doi.org/10.5772/intechopen.92613>.
 30. Sachdeva S, Bhalla S. Semantic interoperability in standardized electronic health record databases. *J Data Inf Qual* 2012;3(1):1–37.
 31. Martinez-Martin N, Magnus D. Privacy and ethical challenges in next-generation sequencing. *Expert Rev Precis Med Drug Dev* 2019;4(2):95–104.
 32. Char DS, Lázaro-Muñoz G, Barnes A, et al. Genomic contraindications for heart transplantation. *Pediatrics* 2017;139(4). <https://doi.org/10.1542/peds.2016-3471>.
 33. A guide to disability rights laws. Available at: <https://www.ada.gov/cguide.htm>. Accessed July 24, 2021.
 34. Genetic discrimination. Available at: <https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination>. Accessed September 18, 2021.
 35. Wall A, Lee GH, Maldonado J, et al. Genetic disease and intellectual disability as contraindications to transplant listing in the United States: a survey of heart, kidney, liver, and lung transplant programs. *Pediatr Transpl* 2020;24(7):e13837.
 36. Lee SS-J, Fullerton SM, Saperstein A, et al. Ethics of inclusion: cultivate trust in precision medicine. *Science* 2019;364(6444):941–2.
 37. Kuhlman C, Jackson L, Chunara R. No computation without representation: avoiding data and algorithm biases through diversity. Available at: <http://arxiv.org/abs/2002.11836>. Accessed September 10, 2021.
 38. Burke W, Edwards KA, Goering S, et al. Achieving justice in genomic translation: re-thinking the pathway to benefit. Oxford University Press; 2011. Available at: <https://play.google.com/store/books/details?id=KA5pAgAAQBAJ>.
 39. Lewis ACF. Where bioethics meets machine ethics. *Am J Bioeth* 2020;20(11):22–4.
 40. Burgart AM, Magnus D, Tabor HK, et al. Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. *JAMA Pediatr* 2018;172(2):188–92.
 41. Chiruvella V, Guddati AK. Ethical issues in patient data ownership. *Interact J Med Res* 2021;10(2):e22269.
 42. Milner LC, Garrison NA, Cho MK, et al. Genomics in the clinic: ethical and policy challenges in clinical next-

- generation sequencing programs at early adopter USA institutions. *Per Med* 2015;12(3):269–82.
43. Cuttillo CM, Sharma KR, Foschini L, et al. Machine intelligence in healthcare-perspectives on trustworthiness, explainability, usability, and transparency. *NPJ Digit Med* 2020;3:47.
 44. Pesapane F, Volonté C, Codari M, et al. Artificial intelligence as a medical device in radiology: ethical and regulatory issues in Europe and the United States. *Insights Imaging* 2018;9(5):745–53.
 45. Institute of Medicine. Board on health sciences policy, committee on Accelerating rare diseases research and orphan Product development. *Rare diseases and orphan Products: Accelerating research and development*. National Academies Press; 2011. Available at: <https://play.google.com/store/books/details?id=HnYyeNlY3WwC>.
 46. Groft SC, Posada M, Taruscio D. Progress, challenges and global approaches to rare diseases. *Acta Paediatr* 2021;9. <https://doi.org/10.1111/apa.15974>.
 47. Valdez R, Ouyang L, Bolen J. Public health and rare diseases: Oxymoron No more. *Prev Chronic Dis* 2016;13:E05.
 48. Allen B, Dreyer K. The role of the ACR data science Institute in advancing health equity in radiology. *J Am Coll Radiol* 2019;16(4 Pt B):644–8.
 49. Zou J, Schiebinger L. Ensuring that biomedical AI benefits diverse populations. *EBioMedicine* 2021; 67:103358.
 50. Fletcher RR, Nakeshimana A, Olubeko O. Addressing fairness, bias, and appropriate use of artificial intelligence and machine learning in global health. *Front Artif Intell* 2020;3:561802.
 51. Hurvitz N, Azmanov H, Kesler A, et al. Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases. *Eur J Hum Genet* 2021; 19. <https://doi.org/10.1038/s41431-021-00928-4>.
 52. Juth N. For the Sake of Justice: should We prioritize rare diseases? *Health Care Anal* 2017;25(1):1–20.
 53. Scherman D. The dynamic and urgent path of rare disease and orphan drug research. *Rare Dis Orphan Drugs J*. Published online 2021. doi: 10.20517/rdodj.2021.01
 54. Morris MA, Saboury B, Burkett B, et al. Reinventing radiology: big data and the future of medical imaging. *J Thorac Imaging* 2018;33(1):4–16.
 55. Hosny A, Parmar C, Quackenbush J, et al. Artificial intelligence in radiology. *Nat Rev Cancer* 2018; 18(8):500–10.
 56. Pirasteh A, Riedl C, Mayerhoefer ME, et al. PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype? *Clin Transl Imaging* 2019;7(6):405–13.
 57. Blumenrath SH, Lee BY, Low L, et al. Tackling rare diseases: clinical trials on chips. *Exp Biol Med* 2020;245(13):1155–62.
 58. de Mello CPP, Rumsey J, Slaughter V, et al. A human-on-a-chip approach to tackling rare diseases. *Drug Discov Today* 2019;24(11):2139–51.
 59. Paul A, Shen TC, Lee S, et al. Generalized Zero-shot Chest X-ray Diagnosis through Trait-Guided Multi-view Semantic Embedding with Self-training. *IEEE Transactions on Medical Imaging*. 2021.
 60. Paul A, Tang YX, Shen TC, et al. Discriminative ensemble learning for few-shot chest x-ray diagnosis. *Medical Image Analysis*. 2021 Feb 1;68: 101911.
 61. Paul A, Tang YX, Summers RM. Fast few-shot transfer learning for disease identification from chest x-ray images using autoencoder ensemble. In *Medical Imaging 2020: Computer-Aided Diagnosis* 2020 Mar 16 (Vol. 11314, p. 1131407). International Society for Optics and Photonics.
 62. Piñol M, Alves R, Teixidó I, et al. Rare disease discovery: an optimized disease ranking system. *IEEE Trans Ind Inf* 2017;13(3):1184–92.
 63. Gurovich Y, Hanani Y, Bar O, et al. Identifying facial phenotypes of genetic disorders using deep learning. *Nat Med* 2019;25(1):60–4.
 64. Ekins S, Puhl AC, Zorn KM, et al. Exploiting machine learning for end-to-end drug discovery and development. *Nat Mater* 2019;18(5):435–41.
 65. Li Q, Zhao K, Bustamante CD, et al. Xrare: a machine learning method jointly modeling phenotypes and genetic evidence for rare disease diagnosis. *Genet Med* 2019;21(9):2126–34.
 66. Progress in fighting rare diseases. Available at: <https://www.phrma.org/en/Media/Progress-in-Fighting-Rare-Diseases>. Accessed July 19, 2021.
 67. Gough A, Soto-Gutierrez A, Verneti L, et al. Human biomimetic liver microphysiology systems in drug development and precision medicine. *Nat Rev Gastroenterol Hepatol* 2021;18(4):252–68.
 68. Hargrove-Grimes P, Low LA, Tagle DA. Microphysiological systems: what it takes for community adoption. *Exp Biol Med* 2021. <https://doi.org/10.1177/15353702211008872>.
 69. Akobeng AK. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. *Acta Paediatr* 2007;96(4):487–91.
 70. Bond RR, Novotny T, Andrsova I, et al. Automation bias in medicine: the influence of automated diagnoses on interpreter accuracy and uncertainty when reading electrocardiograms. *J Electrocardiol* 2018; 51(6S):S6–11.
 71. Rare disease advocacy - NORD's rare action Network™ - NORD (national organization for rare disorders). 2014. Available at: <https://rarediseases.org/for-patient-organizations/ways-partner/advocacy/>. Accessed July 18, 2021.
 72. CME - NORD (National Organization for Rare Disorders). Available at: <https://rarediseases.org/for->

- clinicians-and-researchers/resources/cme/. Accessed July 18, 2021.
73. Chan Zuckerberg. Initiative. Available at: <https://chanzuckerberg.com/>. Accessed September 19, 2021.
 74. Advocacy, Education & Empowerment. Available at: <http://www.geneticalliance.org/>. Accessed July 21, 2021.
 75. Schieppati A, Henter J-I, Daina E, et al. Why rare diseases are an important medical and social issue. *Lancet* 2008;371(9629):2039–41.
 76. Genetic and Rare Diseases Information Center (GARD). Available at: <https://ncats.nih.gov/gard>. Accessed July 6, 2021.
 77. Ali SR, Bryce J, Tan LE, et al. The EuRRECa Project as a model for data access and governance policies for rare disease registries that Collect clinical outcomes. *Int J Environ Res Public Health* 2020; 17(23). <https://doi.org/10.3390/ijerph17238743>.
 78. Saboury B, Morris MA, Farhadi F, et al. Reinventing molecular imaging with total-body PET, Part I: technical revolution in Evolution. *PET Clin* 2020;15(4):427–38.
 79. Prior F, Smith K, Sharma A, et al. The public cancer radiology imaging collections of the Cancer Imaging Archive. *Sci Data* 2017;4:170124.
 80. El Emam K, Rodgers S, Malin B. Anonymising and sharing individual patient data. *BMJ* 2015;350: h1139. <https://doi.org/10.1136/bmj.h1139>.
 81. Courbier S, Dimond R, Bros-Facer V. Share and protect our health data: an evidence based approach to rare disease patients' perspectives on data sharing and data protection - quantitative survey and recommendations. *Orphanet J Rare Dis* 2019;14(1):175.
 82. Spencer K, Sanders C, Whitley EA, et al. Patient perspectives on sharing anonymized personal health data using a digital system for dynamic consent and research feedback: a Qualitative study. *J Med Internet Res* 2016;18(4):e66.
 83. Figueiredo AS. Data sharing: convert challenges into opportunities. *Front Public Health* 2017;5:327.
 84. Rare diseases. Available at: <https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/rare-diseases>. Accessed July 19, 2021.
 85. Find Diseases We Study. Available at: <https://www.rarediseasesnetwork.org/diseases>. Accessed September 19, 2021.
 86. Genetic Alliance - NORD (national organization for rare disorders). 2015. Available at: <https://rarediseases.org/organizations/genetic-alliance/>. Accessed July 6, 2021.
 87. Ghosh P (guha). The impact of data quality in the machine learning era - DATAVERSITY. Available at: <https://www.dataversity.net/impact-data-quality-machine-learning-era/>. Accessed July 17, 2021.
 88. Hallowell N, Parker M, Nellåker C. Big data phenotyping in rare diseases: some ethical issues. *Genet Med* 2019;21(2):272–4.
 89. Yousefirizi F, Jha AK, Brosch-Lenz J, et al. Toward high-Throughput artificial intelligence-based segmentation in oncological PET imaging. *PET Clin* 2021;16(4):577–96.
 90. Arslan M, Guzel M, Demirci M, et al. SMOTE and gaussian noise based sensor data augmentation. In: 2019 4th International Conference on computer science and Engineering (UBMK):Samsun, Turkey; 11-15 Sept. 2019:1-5. doi:10.1109/UBMK.2019.8907003.
 91. dos Santos Tanaka FHK, Aranha C. Data augmentation using GANs. Available at: <http://arxiv.org/abs/1904.09135>.
 92. Mikołajczyk A, Grochowski M. Data augmentation for improving deep learning in image classification problem. In: 2018 International Interdisciplinary PhD Workshop (IIPHDW):Cie, Poland. *ieeexplore.ieee.org*; 9-12 May 2018:117-122. doi:10.1109/IIPHDW.2018.8388338
 93. Frid-Adar M, Diamant I, Klang E, et al. GAN-based synthetic medical image augmentation for increased CNN performance in liver lesion classification. *Neurocomputing* 2018;321:321–31.
 94. Frid-Adar M, Klang E, Amitai M, Goldberger J, Greenspan H. Synthetic data augmentation using GAN for improved liver lesion classification. In: 2018 IEEE 15th International Symposium on Biomedical Imaging:Washington, DC (ISBI 2018). ; 4-7 April 2018:289-293. doi:10.1109/ISBI.2018.8363576
 95. Zheng X, Chalasani T, Ghosal K, Lutz S, Smolic A. STaDA: Style Transfer as Data Augmentation. In: Proceedings of the 14th International Joint Conference on Computer Vision, Imaging and Computer Graphics Theory and Applications:Prague, Czech Republic. SCITEPRESS - Science and Technology Publications; 25-27, 2019. doi: 10.5220/0007353401070114
 96. Qin R, Qiao K, Wang L, Zeng L, Chen J, Yan B. Weighted Focal Loss: An Effective Loss Function to Overcome Unbalance Problem of Chest X-ray14. *IOP Conference Series: Materials Science and Engineering*:Chengdu, China. 19-22 July 2018;428:012022. doi:10.1088/1757-899x/428/1/012022
 97. Zhi-huan ZE-HP. Cost sensitive support vector machines. *Control Decis*. 2006. Available at: https://en.cnki.com.cn/article_en/cjfdtotal-kzyc200604024.htm. Accessed September 10, 2021.
 98. Wei Q, Ren Y, Hou R, et al. Anomaly detection for medical images based on a one-class classification. *Medical imaging* 2018: Computer-Aided diagnosis, 10575. SPIE; 2018. p. 375–80. <https://doi.org/10.1117/12.2293408>.
 99. Ganapathy K. Artificial intelligence and healthcare regulatory and legal concerns. *TMT* 2021. <https://doi.org/10.30953/tmt.v6.252>.

100. Khosla N, Valdez R. A compilation of national plans, policies and government actions for rare diseases in 23 countries. *Intractable Rare Dis Res* 2018;7(4):213–22.
101. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times—the genetic information Nondiscrimination act of 2008. *N Engl J Med* 2008;358(25):2661–3.
102. Melnikova I. Rare diseases and orphan drugs. *Nat Rev Drug Discov* 2012;11(4):267–8.
103. Heemstra HE, van Weely S, Büller HA, et al. Translation of rare disease research into orphan drug development: disease matters. *Drug Discov Today* 2009;14(23–24):1166–73.
104. Liu B, He H, Luo H, et al. Artificial intelligence and big data facilitated targeted drug discovery. *Stroke Vasc Neurol* 2019;4(4):206–13.
105. New study shows the rate of drug approvals lower than previously reported. Available at: <https://archive.bio.org/media/press-release/new-study-shows-rate-drug-approvals-lower-previously-reported>. Accessed September 20, 2021.
106. Wang Y, Li E, Cherry SR, et al. Total-body PET kinetic modeling and potential opportunities using deep learning. *PET Clin* 2021;16(4):613–25.
107. Ataeinia B, Heidari P. Artificial intelligence and the future of diagnostic and therapeutic radiopharmaceutical development. *PET Clin* 2021;16(4):513–23.
108. Saboury B, Morris MA, Nikpanah M, et al. Reinventing molecular imaging with total-body PET, Part II. *PET Clin* 2020;15(4):463–75.
109. Morgenstern J. Why pretest probability is absolutely essential. *First10EM blog*. Published online 2019. doi:10.51684/firs.9601.
110. Nikpanah M, Saboury B, Farhadi F, et al. Pictorial review of the 18F-FDG PET/CT Manifestations of Erdheim-Chester disease. *J Nucl Med* 2019; 60(supplement 1):1141. Available at: https://jnm.snmjournals.org/content/60/supplement_1/1141.short. Accessed September 18, 2021.
111. Cuthbertson DJ, Barriuso J, Lamarca A, et al. The impact of 68Gallium DOTA PET/CT in managing patients with sporadic and familial pancreatic neuroendocrine tumours. *Front Endocrinol* 2021;12:654975. <https://doi.org/10.3389/fendo.2021.654975>.
112. Boér A, Szakáll S Jr, Klein I, et al. FDG PET imaging in hereditary thyroid cancer. *Eur J Surg Oncol* 2003;29(10):922–8.
113. July M, Santhanam P, Giovannella L, et al. Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes. *Clin Physiol Funct Imaging* 2018;38(1):4–9.
114. Duryea DM, Walker ER, Brian PL. Two foci of FDG-avid secondary tumoral calcinosis incidentally noted in a patient with small-cell lung carcinoma after PET/CT. *Radiol Case Rep* 2014;9(4):998.
115. Oh J-R, Kulkarni H, Carreras C, et al. Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau disease. *Nucl Med Mol Imaging* 2012;46(2):129–33.
116. Hughes MS, Azoury SC, Assadipour Y, et al. Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). *Surgery* 2016;159(1):350–6.
117. Čtvrtilík F, Koranda P, Schovánek J, et al. Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy. *Exp Ther Med* 2018;15(4):3151–60.
118. Anand SS, Singh H, Dash AK. Clinical applications of PET and PET-CT. *Armed Forces Med J India* 2009;65(4):353–8.
119. Weisman AJ, Kim J, Lee I, et al. Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients. *EJNMMI Phys* 2020;7(1):76.
120. Yang R, Yu Y. Artificial Convolutional neural Network in Object detection and semantic segmentation for medical imaging Analysis. *Front Oncol* 2021;11:638182. <https://doi.org/10.3389/fonc.2021.638182>.
121. Lee Y-S, Krishnan A, Oughtred R, et al. A Computational Framework for Genome-wide Characterization of the Human Disease Landscape. *Cell Syst* 2019;8(2):152–162.e6.
122. Saboury B, Morris MA, Nikpanah M, et al. Reinventing Molecular Imaging with Total-Body PET, Part II: Clinical Applications [published correction appears in *PET Clin*. 2021 Jan;16(1):xv]. *PET Clin* 2021;15(4):463–75. <https://doi.org/10.1016/j.cpet.2020.06.013>.
123. Saboury B, Morris MA, Farhadi F, et al. Reinventing Molecular Imaging with Total-Body PET, Part I: Technical Revolution in Evolution. *PET Clin* 2020 Oct;15(4):427–38. <https://doi.org/10.1016/j.cpet.2020.06.012>.